Trial
NCT02395627
Reversing Therapy Resistance With Epigenetic-Immune Modification
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
University of California, San Francisco
Collaborators
Avon Foundation; Merck Sharp & Dohme LLC
Condition
Breast Neoplasms
Intervention
Tamoxifen
Why stopped
Insufficient efficacy in an unselected patient population
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-07-07